{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T13:48:09Z","timestamp":1767707289585,"version":"3.41.2"},"reference-count":34,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2024,11,20]],"date-time":"2024-11-20T00:00:00Z","timestamp":1732060800000},"content-version":"vor","delay-in-days":50,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Dar\u00e9 Bioscience"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>A study of topical Sildenafil Cream 3.6% was completed among healthy premenopausal women with female sexual arousal disorder.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Aims<\/jats:title>\n                  <jats:p>To compare efficacy endpoints based on product use in pre-planned and post-hoc subsets of age, race, and medication use.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Phase 2b, exploratory, randomized, placebo-controlled, double-blind study of Sildenafil Cream, 3.6% among healthy premenopausal women with female sexual arousal disorder (FSAD). Eligible participants were randomized 1:1 to Sildenafil versus Placebo Cream and used investigational product for 12\u00a0weeks.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Outcomes<\/jats:title>\n                  <jats:p>The co-primary efficacy endpoints were the change from baseline, at week 12, in the Arousal Sensation (AS) domain of the Sexual Function Questionnaire (SFQ28) and Question 14 (Q14) of the Female Sexual Distress Scale \u2013 Desire, Arousal, Orgasm (FSDS-DAO). The secondary efficacy endpoint was the change from baseline at week 12 in the mean number of satisfactory sexual events (SSEs) reported in a daily diary. Exploratory efficacy endpoints included the Desire and Orgasm domains of the SFQ28.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Age group (\u226518\u00a0years and\u2009\u2264\u200945\u00a0years versus &amp;gt;45\u00a0years), race group (White versus non-White), and baseline use\/non-use of hormonal contraception did not significantly affect the co-primary endpoints of the SFQ28 AS domain and FSDS-DAO Q14 (P values &amp;gt;0.11). Non-White Sildenafil Cream users had an increase in SSEs at week 12 (0.7\u2009\u00b1\u20090.63) while non-white Placebo Cream users reported a decrease (\u22121.5\u2009\u00b1\u20090.58) (P\u2009=\u2009.02). Daily psychiatric medication use among women assigned to either Placebo or Sildenafil Cream resulted in lower SFQ28 Desire domain scores compared to non-users of these medications. Women who used study product only in un-partnered events had a larger improvement in their SFQ28 Orgasm domain scores at week 12 (2.39\u2009\u00b1\u20090.95) with Sildenafil Cream use compared to Placebo (\u22120.19\u2009\u00b1\u20090.75) (P\u2009=\u2009.06). Non-White women represented a higher proportion of un-partnered women and women who used IP only during un-partnered sexual events compared to White women (P\u2009&amp;lt;\u2009.01).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Clinical Implications<\/jats:title>\n                  <jats:p>These pre-planned subset analyses will help refine target populations in future studies of Sildenafil Cream, 3.6% for the treatment of FSAD.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Strengths and Limitations<\/jats:title>\n                  <jats:p>Subset analyses focused on variables pertinent to future target populations. The current study population was primarily educated non-Hispanic White women.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Age and hormonal contraceptive use did not impact the efficacy of topical Sildenafil Cream. Daily psychiatric medication use decreased sexual desire in active and placebo users.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/sexmed\/qfae079","type":"journal-article","created":{"date-parts":[[2024,11,20]],"date-time":"2024-11-20T02:19:48Z","timestamp":1732069188000},"source":"Crossref","is-referenced-by-count":1,"title":["Impact of age, race, and medication use on efficacy endpoints in a randomized controlled trial of topical sildenafil cream for the treatment of female sexual arousal disorder"],"prefix":"10.1093","volume":"12","author":[{"given":"Isabella","family":"Johnson","sequence":"first","affiliation":[{"name":"Dar\u00e9 Bioscience , San Diego, CA,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea Ries","family":"Thurman","sequence":"additional","affiliation":[{"name":"Dar\u00e9 Bioscience , San Diego, CA,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katherine A","family":"Cornell","sequence":"additional","affiliation":[{"name":"Strategic Science & Technologies, LLC , Cambridge, MA,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clint","family":"Dart","sequence":"additional","affiliation":[{"name":"Premier Research , Morrisville, NC,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessica","family":"Hatheway","sequence":"additional","affiliation":[{"name":"Dar\u00e9 Bioscience , San Diego, CA,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David R","family":"Friend","sequence":"additional","affiliation":[{"name":"Dar\u00e9 Bioscience , San Diego, CA,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Goldstein","sequence":"additional","affiliation":[{"name":"Dar\u00e9 Bioscience , San Diego, CA,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2024,11,19]]},"reference":[{"issue":"1","key":"2024112002193472800_ref1","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.sxmr.2020.05.001","article-title":"The evolution of the female sexual disorder\/dysfunction definitions, nomenclature, and classifications: a review of DSM, ICSM, ISSWSH, and ICD","volume":"9","author":"Parish","year":"2021","journal-title":"Sex Med Rev"},{"issue":"2","key":"2024112002193472800_ref2","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1007\/s10508-009-9535-1","article-title":"The DSM diagnostic criteria for female sexual arousal disorder","volume":"39","author":"Graham","year":"2010","journal-title":"Arch Sex Behav"},{"issue":"5","key":"2024112002193472800_ref3","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1345\/aph.1G471","article-title":"Use of sildenafil for female sexual dysfunction","volume":"40","author":"Shields","year":"2006","journal-title":"Ann Pharmacother"},{"issue":"4","key":"2024112002193472800_ref4","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1038\/nrurol.2009.25","article-title":"Sildenafil citrate for female sexual arousal disorder: a future possibility?","volume":"6","author":"Schoen","year":"2009","journal-title":"Nat Rev Urol"},{"issue":"7-8","key":"2024112002193472800_ref5","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1345\/aph.1L691","article-title":"Assessing the clinical efficacy of sildenafil for the treatment of female sexual dysfunction","volume":"43","author":"Brown","year":"2009","journal-title":"Ann Pharmacother"},{"issue":"2_Part_2","key":"2024112002193472800_ref6","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1111\/j.1743-6109.2009.01599.x","article-title":"Phosphodiesterase type 5 inhibitors and female sexual response: faulty protocols or paradigms?","volume":"7","author":"Chivers","year":"2010","journal-title":"J Sex Med"},{"issue":"6","key":"2024112002193472800_ref7","doi-asserted-by":"publisher","first-page":"2333","DOI":"10.1097\/01.ju.0000090966.74607.34","article-title":"Safety and efficacy of sildenafil citrate for the treatment of female sexual arousal disorder: a double-blind, placebo controlled study","volume":"170","author":"Berman","year":"2003","journal-title":"J Urol"},{"issue":"5","key":"2024112002193472800_ref8","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1016\/j.fertnstert.2005.10.043","article-title":"Sildenafil improves sexual functioning in premenopausal women with type 1 diabetes who are affected by sexual arousal disorder: a double-blind, crossover, placebo-controlled pilot study","volume":"85","author":"Caruso","year":"2006","journal-title":"Fertil Steril"},{"issue":"4","key":"2024112002193472800_ref9","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1001\/jama.300.4.395","article-title":"Sildenafil treatment of women with antidepressant-associated sexual dysfunction: a randomized controlled trial","volume":"300","author":"Nurnberg","year":"2008","journal-title":"JAMA"},{"issue":"2","key":"2024112002193472800_ref10","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1097\/AOG.0000000000005648","article-title":"Preliminary efficacy of topical sildenafil cream for the treatment of female sexual arousal disorder: a randomized controlled trial","volume":"144","author":"Johnson","year":"2024","journal-title":"Obstet Gynecol"},{"issue":"9","key":"2024112002193472800_ref11","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1093\/jsxmed\/qdae086","article-title":"Comparisons and correlations of 1-month recall vs 24-hour recall in patient-reported outcomes of an exploratory, phase 2b, randomized, double-blind, placebo-controlled clinical trial of sildenafil cream, 3.6% for the treatment of female sexual arousal disorder","volume":"21","author":"Johnson","year":"2024","journal-title":"J Sex Med"},{"issue":"9","key":"2024112002193472800_ref12","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1093\/jsxmed\/qdae089","article-title":"Safety of topical sildenafil cream, 3.6% in a randomized, placebo-controlled trial for the treatment of female sexual arousal disorder","volume":"21","author":"Thurman","year":"2024","journal-title":"J Sex Med"},{"issue":"10","key":"2024112002193472800_ref13","doi-asserted-by":"publisher","first-page":"2609","DOI":"10.1111\/j.1743-6109.2011.02627.x","article-title":"Sexual function questionnaire: further refinement and validation","volume":"9","author":"Symonds","year":"2012","journal-title":"J Sex Med"},{"issue":"4","key":"2024112002193472800_ref14","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1111\/j.1743-6109.2005.00076.x","article-title":"The use of the sexual function questionnaire as a screening tool for women with sexual dysfunction","volume":"2","author":"Quirk","year":"2005","journal-title":"J Sex Med"},{"issue":"6","key":"2024112002193472800_ref15","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1017\/S002193201900083X","article-title":"Sexual activity by marital status and age: a comparative perspective","volume":"52","author":"Ueffing","year":"2020","journal-title":"J Biosoc Sci"},{"issue":"3","key":"2024112002193472800_ref16","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.whi.2020.12.009","article-title":"Contraceptive method use by rural-urban residence among women and men in the United States, 2006 to 2017","volume":"31","author":"Janis","year":"2021","journal-title":"Womens Health Issues"},{"issue":"3","key":"2024112002193472800_ref17","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1093\/sxmrev\/qeae011","article-title":"Combined estrogen-progestin oral contraceptives and female sexuality: an updated review. Sex","volume":"12","author":"Krapf","year":"2024","journal-title":"Med Rev"},{"issue":"8","key":"2024112002193472800_ref18","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1093\/jsxmed\/qdad072","article-title":"Reduction in genital sexual arousal varies by type of oral contraceptive pill","volume":"20","author":"Handy","year":"2023","journal-title":"J Sex Med"},{"issue":"11","key":"2024112002193472800_ref19","doi-asserted-by":"publisher","first-page":"4046","DOI":"10.1210\/jc.2016-2032","article-title":"Combined oral contraceptives and sexual function in women-a double-blind, randomized, placebo-controlled trial","volume":"101","author":"Zethraeus","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2024112002193472800_ref20","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1080\/13625187.2016.1217324","article-title":"The effect of a drospirenone-containing combined oral contraceptive on female sexual function: a prospective randomised study","volume":"21","author":"Ciaplinskiene","year":"2016","journal-title":"Eur J Contracept Reprod Health Care"},{"issue":"2","key":"2024112002193472800_ref21","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1097\/AOG.0000000000003073","article-title":"206 summary: use of hormonal contraception in women with coexisting medical conditions","volume":"133","author":"ACOG Practice Bulletin No","year":"2019","journal-title":"Obstet Gynecol"},{"issue":"7","key":"2024112002193472800_ref22","doi-asserted-by":"publisher","first-page":"e2323746","DOI":"10.1001\/jamanetworkopen.2023.23746","article-title":"Reasons for discontinuation or change of selective serotonin reuptake inhibitors in online drug reviews","volume":"6","author":"Golder","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"6","key":"2024112002193472800_ref23","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1007\/s40264-022-01174-3","article-title":"Drug-induced sexual dysfunction: an analysis of reports to a National Pharmacovigilance Database","volume":"45","author":"Valeiro","year":"2022","journal-title":"Drug Saf"},{"issue":"4","key":"2024112002193472800_ref24","doi-asserted-by":"publisher","first-page":"321","DOI":"10.3233\/JRS-210039","article-title":"Characterizing post-SSRI sexual dysfunction and its impact on quality of life through an international online survey","volume":"32","author":"Studt","year":"2021","journal-title":"Int J Risk Saf Med"},{"issue":"11","key":"2024112002193472800_ref25","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1089\/jwh.2022.0484","article-title":"Age-dependent sex differences in the prevalence of selective serotonin reuptake inhibitor treatment: a retrospective cohort analysis","volume":"32","author":"Sanchez-Ruiz","year":"2023","journal-title":"J Women's Health (Larchmt)"},{"issue":"2","key":"2024112002193472800_ref26","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1007\/s00404-022-06810-y","article-title":"The complexity of female orgasm and ejaculation","volume":"308","author":"Arias-Castillo","year":"2023","journal-title":"Arch Gynecol Obstet"},{"issue":"6","key":"2024112002193472800_ref27","doi-asserted-by":"publisher","first-page":"3151","DOI":"10.1007\/s10508-022-02305-8","article-title":"A seemingly paradoxical relationship between masturbation frequency and sexual satisfaction","volume":"51","author":"Fischer","year":"2022","journal-title":"Arch Sex Behav"},{"key":"2024112002193472800_ref28","doi-asserted-by":"publisher","first-page":"903361","DOI":"10.3389\/fpsyt.2022.903361","article-title":"Masturbation parameters related to orgasm satisfaction in sexual relationships: differences between men and women","volume":"13","author":"Cervilla","year":"2022","journal-title":"Front Psychiatry"},{"issue":"4","key":"2024112002193472800_ref29","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1111\/j.1743-6109.2011.02626.x","article-title":"Treatment of hypoactive sexual desire disorder in premenopausal women: efficacy of flibanserin in the VIOLET study","volume":"9","author":"Derogatis","year":"2012","journal-title":"J Sex Med"},{"issue":"7","key":"2024112002193472800_ref30","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.1111\/jsm.12189","article-title":"Efficacy of flibanserin in women with hypoactive sexual desire disorder: results from the BEGONIA trial","volume":"10","author":"Katz","year":"2013","journal-title":"J Sex Med"},{"issue":"3","key":"2024112002193472800_ref31","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1111\/j.1743-6109.2011.02595.x","article-title":"Treatment of hypoactive sexual desire disorder in premenopausal women: efficacy of flibanserin in the DAISY study","volume":"9","author":"Thorp","year":"2012","journal-title":"J Sex Med"},{"issue":"6","key":"2024112002193472800_ref32","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1089\/jwh.2018.7516","article-title":"Flibanserin for premenopausal hypoactive sexual desire disorder: pooled analysis of clinical trials","volume":"28","author":"Simon","year":"2019","journal-title":"J Women's Health (Larchmt)"},{"issue":"5","key":"2024112002193472800_ref33","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1097\/AOG.0000000000003514","article-title":"Long-term safety and efficacy of Bremelanotide for hypoactive sexual desire disorder","volume":"134","author":"Simon","year":"2019","journal-title":"Obstet Gynecol"},{"issue":"5","key":"2024112002193472800_ref34","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1097\/AOG.0000000000003500","article-title":"Bremelanotide for the treatment of hypoactive sexual desire disorder: two randomized phase 3 trials","volume":"134","author":"Kingsberg","year":"2019","journal-title":"Obstet Gynecol"}],"container-title":["Sexual Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/smoa\/article-pdf\/12\/5\/qfae079\/60751337\/qfae079.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/smoa\/article-pdf\/12\/5\/qfae079\/60751337\/qfae079.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,20]],"date-time":"2024-11-20T02:20:00Z","timestamp":1732069200000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/smoa\/article\/doi\/10.1093\/sexmed\/qfae079\/7904770"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,1]]},"references-count":34,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,10,1]]}},"URL":"https:\/\/doi.org\/10.1093\/sexmed\/qfae079","relation":{},"ISSN":["2050-1161"],"issn-type":[{"type":"electronic","value":"2050-1161"}],"subject":[],"published-other":{"date-parts":[[2024,10]]},"published":{"date-parts":[[2024,10,1]]},"article-number":"qfae079"}}